Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled clinical trial

Objective The main aim of this study is to evaluate the efficacy of reboxetine, a specific noradrenergic reuptake inhibitor, in adults with attention‐deficit/hyperactivity disorder (ADHD). Methods In a double blind placebo‐controlled clinical trial, the efficacy of 8 mg/day of reboxetine (twice daily) was compared with placebo in 40 adults diagnosed with ADHD during 6 weeks. The measures were Conners' Adult ADHD Rating Scale‐Self‐Report, Screening Version (CAARS‐S, SV), Hamilton Anxiety and Depression Rating Scales, Clinical Global Impression – Severity Scale (CGI‐S), and Global Assessment of Functioning Scale (GAF). Results There was a main effect of time and significant time X treatment (reboxetine vs. placebo) interaction on CAARS subscales and CGI scores which decreased along the study (p